326 related articles for article (PubMed ID: 24809802)
1. High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.
Chirico V; Lacquaniti A; Salpietro V; Munafò C; Calabrò MP; Buemi M; Arrigo T; Salpietro C
Eur J Pediatr; 2014 Sep; 173(9):1123-36. PubMed ID: 24809802
[TBL] [Abstract][Full Text] [Related]
2. High-mobility group box 1 inhibits gastric ulcer healing through Toll-like receptor 4 and receptor for advanced glycation end products.
Nadatani Y; Watanabe T; Tanigawa T; Ohkawa F; Takeda S; Higashimori A; Sogawa M; Yamagami H; Shiba M; Watanabe K; Tominaga K; Fujiwara Y; Takeuchi K; Arakawa T
PLoS One; 2013; 8(11):e80130. PubMed ID: 24244627
[TBL] [Abstract][Full Text] [Related]
3. High mobility group box 1 protein interacts with multiple Toll-like receptors.
Park JS; Gamboni-Robertson F; He Q; Svetkauskaite D; Kim JY; Strassheim D; Sohn JW; Yamada S; Maruyama I; Banerjee A; Ishizaka A; Abraham E
Am J Physiol Cell Physiol; 2006 Mar; 290(3):C917-24. PubMed ID: 16267105
[TBL] [Abstract][Full Text] [Related]
4. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease.
Pisetsky DS; Erlandsson-Harris H; Andersson U
Arthritis Res Ther; 2008; 10(3):209. PubMed ID: 18598385
[TBL] [Abstract][Full Text] [Related]
5. Targeting high mobility group box protein 1 ameliorates testicular inflammation in experimental autoimmune orchitis.
Aslani F; Schuppe HC; Guazzone VA; Bhushan S; Wahle E; Lochnit G; Lustig L; Meinhardt A; Fijak M
Hum Reprod; 2015 Feb; 30(2):417-31. PubMed ID: 25452436
[TBL] [Abstract][Full Text] [Related]
6. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
7. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
Urbonaviciute V; Voll RE
J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
[TBL] [Abstract][Full Text] [Related]
8. HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease.
Chandrashekaran V; Seth RK; Dattaroy D; Alhasson F; Ziolenka J; Carson J; Berger FG; Kalyanaraman B; Diehl AM; Chatterjee S
Redox Biol; 2017 Oct; 13():8-19. PubMed ID: 28551086
[TBL] [Abstract][Full Text] [Related]
9. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.
Yu M; Wang H; Ding A; Golenbock DT; Latz E; Czura CJ; Fenton MJ; Tracey KJ; Yang H
Shock; 2006 Aug; 26(2):174-9. PubMed ID: 16878026
[TBL] [Abstract][Full Text] [Related]
10. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.
Musumeci D; Roviello GN; Montesarchio D
Pharmacol Ther; 2014 Mar; 141(3):347-57. PubMed ID: 24220159
[TBL] [Abstract][Full Text] [Related]
11. HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response.
Lu M; Yu S; Xu W; Gao B; Xiong S
J Immunol Res; 2015; 2015():946748. PubMed ID: 26078984
[TBL] [Abstract][Full Text] [Related]
12. High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia.
Qiu J; Xu J; Zheng Y; Wei Y; Zhu X; Lo EH; Moskowitz MA; Sims JR
Stroke; 2010 Sep; 41(9):2077-82. PubMed ID: 20671243
[TBL] [Abstract][Full Text] [Related]
13. High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule.
Yang H; Wang H; Chavan SS; Andersson U
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S6-S12. PubMed ID: 26605648
[TBL] [Abstract][Full Text] [Related]
14. Review: Therapeutic Targeting of HMGB1 in Stroke.
Tian X; Liu C; Shu Z; Chen G
Curr Drug Deliv; 2017 Sep; 14(6):785-790. PubMed ID: 27501713
[TBL] [Abstract][Full Text] [Related]
15. Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice.
Chen X; Ma J; Kwan T; Stribos EGD; Messchendorp AL; Loh YW; Wang X; Paul M; Cunningham EC; Habib M; Alexander IE; Sharland AF; Chadban SJ; Wu H
Sci Rep; 2018 May; 8(1):8319. PubMed ID: 29844451
[TBL] [Abstract][Full Text] [Related]
16. HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development.
Abdulahad DA; Westra J; Limburg PC; Kallenberg CG; Bijl M
Autoimmun Rev; 2010 Aug; 9(10):661-5. PubMed ID: 20546955
[TBL] [Abstract][Full Text] [Related]
17. Implication of HMGB1 signaling pathways in Amyotrophic lateral sclerosis (ALS): From molecular mechanisms to pre-clinical results.
Paudel YN; Angelopoulou E; Piperi C; Othman I; Shaikh MF
Pharmacol Res; 2020 Jun; 156():104792. PubMed ID: 32278047
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue.
Casula M; Iyer AM; Spliet WG; Anink JJ; Steentjes K; Sta M; Troost D; Aronica E
Neuroscience; 2011 Apr; 179():233-43. PubMed ID: 21303685
[TBL] [Abstract][Full Text] [Related]
19. Role of the high mobility group box 1 signalling axes via the receptor for advanced glycation end-products and toll-like receptor-4 in the immunopathology of oral lichen planus: a potential drug target?
Salem A; Almahmoudi R; Vehviläinen M; Salo T
Eur J Oral Sci; 2018 Jun; 126(3):244-248. PubMed ID: 29676511
[TBL] [Abstract][Full Text] [Related]
20. High-mobility group box 1 inhibits HCO(3)(-) absorption in medullary thick ascending limb through a basolateral receptor for advanced glycation end products pathway.
Good DW; George T; Watts BA
Am J Physiol Renal Physiol; 2015 Oct; 309(8):F720-30. PubMed ID: 26180239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
